Categories: DrugEngineeringHealthTechIndustryManufacturingMedtechPlatformProductionTechnology
Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical industry.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.05.2025 | - | $6.26M | - |
Mentions in press and media 6
| Date | Title | Description |
| 29.05.2025 | Kyron.bio: Pioneering a New Era in Antibody Therapeutics | In the bustling world of biotechnology, a new player is making waves. Kyron.bio, a Paris-based startup, has secured €5.5 million in seed funding to revolutionize drug development. This funding is not just a financial boost; it’s a lifeline ... |
| 29.05.2025 | Kyron.bio Raises €5.5M in Funding | Kyron.bio, a Paris, France-based glycan engineering startup, raised €5.5m in funding.
The round was led by HCVC with participaiton from Verve Ventures, Entrepreneur First, and Saras Capital.
The company intends to use the funds to expand op... |
| 28.05.2025 | Kyron.bio raises €5.5M to transform antibody design | One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects.
Biotechnology company Kyron.bio has raised €5.5 million funding to solve these issues using precise control of sugar molecul... |
| 28.05.2025 | Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering | What You Should Know:
– Biotechnology company kyron.bio announced the successful closing of a $6.2M (€5.5M) seed funding round aimed at solving critical challenges in biologic drug development, specifically varying efficacy and the dangers ... |
| 28.05.2025 | Paris-based kyron.bio secures €5.5 million to tackle drug efficiency and safety | French BioTech company kyron.bio announced today a €5.5 million Seed funding round to tackle the issues of varying efficacy and dangerous side effects in current drug development, using control of sugar molecules – also known as glycans.
Th... |
| - | Kyron.bio | “Home | Kyron.bio ” |
Reviews 0
